Free Trial
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free ESPR Stock Alerts

Esperion Therapeutics (ESPR) Financials

Esperion Therapeutics logo
$3.13 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$3.12 0.00 (-0.16%)
As of 06:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Esperion Therapeutics

Annual Income Statements for Esperion Therapeutics

This table shows Esperion Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -50 -75 -167 -202 -97 -144 -269 -234 -209 -52 -23
Consolidated Net Income / (Loss)		 -50 -75 -167 -202 -97 -144 -269 -234 -209 -52 -23
Net Income / (Loss) Continuing Operations		 -50 -75 -167 -202 -97 -144 -269 -234 -209 -52 -23
Total Pre-Tax Income 		-51 -76 -169 -205 -101 -144 -273 -234 -209 -52 -21
Total Operating Income		 -50 -76 -169 -205 -93 -121 -227 -180 -156 54 60
Total Gross Profit		 0.00 0.00 0.00 0.00 148 228 78 75 73 264 274
Total Revenue		 0.00 0.00 0.00 0.00 148 228 78 75 116 332 403
Operating Revenue		 - - - 0.00 148 228 78 75 116 332 403
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 43 69 129
Operating Cost of Revenue		 - - - - - - - - 43 69 129
Total Operating Expenses		 50 76 169 205 241 349 305 255 229 209 214
Selling, General & Admin Expense		 20 18 21 33 66 202 199 136 143 163 166
Research & Development Expense		 30 58 148 171 176 147 106 119 86 46 48
Total Other Income / (Expense), net		 -0.52 0.00 -0.20 -0.03 -8.12 -23 -46 -54 -54 -106 -81
Interest Expense		 0.52 - 0.20 0.03 8.12 23 46 57 59 114 85
Other Income / (Expense), net		 - - - - - - - 2.65 5.29 8.02 3.49
Income Tax Expense		 - - - - - - - - 0.00 0.00 1.84
Basic Earnings per Share		 ($2.26) ($3.33) ($6.98) ($7.54) ($3.59) ($5.23) ($9.31) ($3.52) ($2.03) ($0.28) ($0.11)
Weighted Average Basic Shares Outstanding		 22.02M 22.54M 23.93M 26.75M 27.09M 27.47M 28.90M 66.41M 103.11M 187.18M 207.87M
Diluted Earnings per Share		 ($2.26) ($3.33) ($6.98) ($7.54) ($3.59) ($5.23) ($9.31) ($3.52) ($2.03) ($0.28) ($0.11)
Weighted Average Diluted Shares Outstanding		 22.02M 22.54M 23.93M 26.75M 27.09M 27.47M 28.90M 66.41M 103.11M 187.18M 207.87M
Weighted Average Basic & Diluted Shares Outstanding		 22.02M 22.54M 23.93M 26.75M 27.09M 27.47M 62.82M 76.57M 185.05M 197.85M 256.81M

Quarterly Income Statements for Esperion Therapeutics

This table shows Esperion Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -41 -56 61 -62 -30 -21 -40 -13 -31 62 -25
Consolidated Net Income / (Loss)		 -41 -56 61 -62 -30 -21 -40 -13 -31 62 -25
Net Income / (Loss) Continuing Operations		 -41 -56 61 -62 -30 -21 -40 -13 -31 62 -25
Total Pre-Tax Income 		-43 -53 58 -64 -30 38 -42 -13 -32 66 -26
Total Operating Income		 -28 -42 72 2.58 -16 -4.42 -22 7.10 -9.96 85 -6.58
Total Gross Profit		 34 -11 138 74 52 69 65 82 87 39 80
Total Revenue		 34 32 138 74 52 69 65 82 87 168 80
Operating Revenue		 34 32 138 74 52 69 65 82 87 168 80
Total Cost of Revenue		 0.00 43 0.00 0.00 0.00 - 0.00 0.00 0.00 129 0.00
Total Operating Expenses		 62 31 65 71 68 74 87 75 97 -46 87
Selling, General & Admin Expense		 47 14 52 60 57 63 75 68 83 -60 78
Research & Development Expense		 15 18 13 11 10 11 13 7.24 14 14 8.99
Total Other Income / (Expense), net		 -15 -11 -14 -67 -13 42 -19 -20 -22 -19 -20
Interest Expense		 15 15 14 67 15 -37 19 20 22 23 20
Other Gains / (Losses), net		 1.28 - 2.78 2.45 - - 1.07 0.67 0.68 - 1.18
Basic Earnings per Share		 ($0.37) ($0.41) $0.36 ($0.33) ($0.15) ($0.16) ($0.21) ($0.06) ($0.16) $0.32 ($0.10)
Weighted Average Basic Shares Outstanding		 111.87M 103.11M 169.26M 188.79M 194.93M 187.18M 196.13M 197.55M 200.74M 207.87M 251.35M
Diluted Earnings per Share		 ($0.37) ($0.41) $0.34 ($0.33) ($0.15) ($0.14) ($0.21) ($0.06) ($0.16) $0.32 ($0.10)
Weighted Average Diluted Shares Outstanding		 111.87M 103.11M 189.64M 188.79M 194.93M 187.18M 196.13M 197.55M 200.74M 207.87M 251.35M
Weighted Average Basic & Diluted Shares Outstanding		 113.72M 185.05M 189.46M 196.22M 197.04M 197.85M 198.20M 201.62M 239.06M 256.81M 257.43M

Annual Cash Flow Statements for Esperion Therapeutics

This table details how cash moves in and out of Esperion Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -7.70 -39 -3.70 2.51 130 138 -46 -134 -43 63 23
Net Cash From Operating Activities		 -38 -48 -131 -149 -70 -85 -264 -175 -135 -24 -13
Net Cash From Continuing Operating Activities		 -38 -48 -131 -149 -70 -85 -264 -175 -135 -24 -13
Net Income / (Loss) Continuing Operations		 -50 -75 -167 -202 -97 -144 -269 -234 -209 -52 -23
Consolidated Net Income / (Loss)		 -50 -75 -167 -202 -97 -144 -269 -234 -209 -52 -23
Depreciation Expense		 0.24 0.25 0.26 0.27 0.32 0.55 0.61 0.50 0.16 0.06 0.11
Amortization Expense		 0.71 1.01 0.33 -0.22 -0.20 1.64 1.63 1.90 1.29 1.50 3.01
Non-Cash Adjustments To Reconcile Net Income		 13 16 19 24 34 60 56 60 59 87 21
Changes in Operating Assets and Liabilities, net		 -2.09 10 16 29 -7.30 -4.26 -53 -3.37 14 -61 -15
Net Cash From Investing Activities		 -160 10 -36 140 64 21 -50 8.10 43 -0.32 0.00
Net Cash From Continuing Investing Activities		 -160 10 -36 140 64 21 -50 8.10 43 -0.32 0.00
Purchase of Property, Plant & Equipment		 -0.33 -0.09 -0.02 -0.15 -0.95 -0.87 - 0.00 0.00 -0.32 0.00
Sale and/or Maturity of Investments		 121 207 184 166 100 39 0.00 68 43 0.00 0.00
Net Cash From Financing Activities		 191 -1.56 163 11 136 202 268 33 50 86 36
Net Cash From Continuing Financing Activities		 191 -1.56 163 11 136 202 269 33 50 86 36
Repayment of Debt		 -0.64 -1.60 -1.71 -1.05 0.00 -8.41 -0.44 -0.22 0.02 -220 -55
Repurchase of Preferred Equity		 - - - - - - - - 0.00 -344 0.00
Repurchase of Common Equity		 - - - 0.00 0.00 -55 - -50 0.00 0.00 -7.50
Issuance of Debt		 - - - 0.00 124 280 50 0.00 0.00 245 0.00
Issuance of Common Equity		 190 0.00 164 - 0.00 0.00 219 91 57 91 88
Other Financing Activities, net		 1.18 0.05 1.17 12 12 -15 0.37 -8.02 -6.44 314 10
Cash Interest Paid		 - - - - - - - - 11 11 16
Cash Income Taxes Paid		 - - - - - - - - 0.00 0.00 0.61

Quarterly Cash Flow Statements for Esperion Therapeutics

This table details how cash moves in and out of Esperion Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -24 -33 144 -37 -45 0.04 -30 -29 6.39 75 -12
Net Cash From Operating Activities		 -19 -37 54 -7.21 -35 -35 -23 -31 -4.29 45 -28
Net Cash From Continuing Operating Activities		 -19 -37 54 -7.21 -35 -35 -23 -31 -4.29 45 -28
Net Income / (Loss) Continuing Operations		 -41 -56 61 -62 -30 -21 -40 -13 -31 62 -25
Consolidated Net Income / (Loss)		 -41 -56 61 -62 -30 -21 -40 -13 -31 62 -25
Depreciation Expense		 0.03 0.01 0.00 0.01 0.03 0.03 0.03 0.03 0.03 0.03 0.03
Amortization Expense		 0.43 0.43 0.44 0.44 0.45 0.17 0.70 0.82 0.85 0.64 0.59
Non-Cash Adjustments To Reconcile Net Income		 15 15 14 59 6.15 7.48 5.07 6.77 5.21 4.07 -2.09
Changes in Operating Assets and Liabilities, net		 6.58 3.96 -22 -5.00 -12 -21 12 -26 21 -21 -1.06
Net Cash From Investing Activities		 - - -0.07 -0.08 -0.17 - 0.00 - - - -0.19
Net Cash From Continuing Investing Activities		 - - -0.07 -0.08 -0.17 - 0.00 - - - -0.19
Purchase of Property, Plant & Equipment		 - - -0.07 -0.08 -0.17 - 0.00 - - - -0.19
Net Cash From Financing Activities		 -4.31 4.47 91 -30 -9.10 35 -7.50 2.85 11 30 16
Net Cash From Continuing Financing Activities		 -4.31 4.47 91 -30 -9.10 35 -7.50 2.85 11 30 16
Repurchase of Common Equity		 - - 0.00 - - - -7.50 - - - 0.00
Other Financing Activities, net		 -4.28 4.45 -0.07 314 - -9.66 0.00 - 0.14 10 16

Annual Balance Sheets for Esperion Therapeutics

This table presents Esperion Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 296 245 278 143 214 353 382 248 206 344 466
Total Current Assets		 214 214 204 143 212 346 329 247 201 338 463
Cash & Equivalents		 77 38 34 37 166 305 209 125 82 145 168
Accounts Receivable		 - - - - - 12 23 34 48 80 140
Inventories, net		 - - - - 0.00 16 34 35 66 108 146
Prepaid Expenses		 2.13 1.99 3.73 6.61 10 12 12 11 4.70 4.74 8.54
Plant, Property, & Equipment, net		 0.81 0.67 0.44 0.52 1.15 1.28 0.66 0.16 0.00 0.25 0.34
Total Noncurrent Assets		 80 31 73 0.30 1.59 6.09 52 1.09 4.73 5.57 2.98
Goodwill		 - - - - - - - 0.06 0.06 0.06 0.06
Other Noncurrent Operating Assets		 - - - - 1.53 6.03 52 1.04 4.68 5.51 2.92
Total Liabilities & Shareholders' Equity		 296 245 278 143 214 353 382 248 206 344 466
Total Liabilities		 8.31 17 33 64 194 449 579 572 661 733 768
Total Current Liabilities		 5.63 16 33 64 66 94 73 92 156 246 301
Accounts Payable		 0.71 4.60 20 45 29 52 18 23 32 52 65
Accrued Expenses		 3.31 9.29 12 19 29 32 37 41 63 81 112
Current Deferred Revenue		 - - - - 2.15 1.66 5.68 3.51 25 8.52 34
Other Current Liabilities		 - - - - 5.69 7.98 13 25 36 50 90
Total Noncurrent Liabilities		 2.69 1.02 0.00 0.00 128 355 505 479 505 486 467
Long-Term Debt		 2.69 1.02 - - 0.00 179 258 260 262 238 249
Other Noncurrent Operating Liabilities		 - - - - 128 176 246 220 243 249 218
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 287 229 245 79 20 -96 -197 -324 -455 -389 -302
Total Preferred & Common Equity		 287 229 245 79 20 -96 -197 -324 -455 -389 -302
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 287 229 245 79 20 -96 -197 -324 -455 -389 -302
Common Stock		 442 458 642 678 715 798 964 1,071 1,149 1,267 1,377
Retained Earnings		 -154 -229 -396 -598 -695 -839 -1,106 -1,340 -1,549 -1,601 -1,624
Treasury Stock		 - - - - 0.00 -55 -55 -55 -55 -55 -55

Quarterly Balance Sheets for Esperion Therapeutics

This table presents Esperion Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 235 221 373 352 314 324 347 364 463
Total Current Assets		 232 218 366 345 308 319 343 360 459
Cash & Equivalents		 138 115 227 189 145 115 86 92 156
Accounts Receivable		 41 43 55 60 68 81 108 119 132
Inventories, net		 46 51 73 84 80 118 139 142 159
Prepaid Expenses		 7.18 9.34 11 11 15 5.32 9.55 7.20 12
Plant, Property, & Equipment, net		 0.03 0.01 0.27 0.31 0.28 0.23 0.20 0.18 0.31
Total Noncurrent Assets		 2.47 3.07 7.19 6.90 6.28 5.02 4.29 3.38 2.76
Goodwill		 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06
Other Noncurrent Operating Assets		 2.41 3.02 7.13 6.85 6.22 4.97 4.23 3.33 2.70
Total Liabilities & Shareholders' Equity		 235 221 373 352 314 324 347 364 463
Total Liabilities		 607 631 667 697 684 750 781 815 770
Total Current Liabilities		 107 138 165 175 166 271 299 359 300
Accounts Payable		 25 26 28 48 35 72 75 78 68
Accrued Expenses		 44 54 61 72 75 80 78 99 106
Current Deferred Revenue		 16 20 29 21 15 4.54 22 31 44
Other Current Liabilities		 23 38 46 35 41 60 69 97 82
Total Noncurrent Liabilities		 499 494 503 521 518 479 482 456 470
Long-Term Debt		 261 261 262 262 263 238 243 249 250
Other Noncurrent Operating Liabilities		 239 232 241 259 256 241 238 208 220
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -372 -410 -294 -344 -370 -426 -434 -451 -308
Total Preferred & Common Equity		 -372 -410 -294 -344 -370 -426 -434 -451 -308
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -372 -410 -294 -344 -370 -426 -434 -451 -308
Common Stock		 1,135 1,138 1,249 1,261 1,265 1,270 1,276 1,289 1,396
Retained Earnings		 -1,452 -1,493 -1,488 -1,550 -1,580 -1,641 -1,654 -1,686 -1,649
Treasury Stock		 -55 -55 -55 -55 -55 -55 -55 -55 -55

Annual Metrics And Ratios for Esperion Therapeutics

This table displays calculated financial ratios and metrics derived from Esperion Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 22,518,907.00 22,553,851.00 26,197,749.00 26,811,002.00 27,327,409.00 27,876,626.00 29,077,357.00 73,683,572.00 113,717,785.00 - 239,063,437.00
DEI Adjusted Shares Outstanding		 22,518,907.00 22,553,851.00 26,197,749.00 26,811,002.00 27,327,409.00 27,876,626.00 29,077,357.00 73,683,572.00 113,717,785.00 - 239,063,437.00
DEI Earnings Per Adjusted Shares Outstanding		 -2.21 -3.32 -6.37 -7.53 -3.56 -5.15 -9.25 -3.17 -1.84 - -0.09
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -35 -53 -118 -143 -65 -85 -159 -126 -109 54 42
Return On Investment Capital (ROIC_SIMPLE)		 - - - -181.01% - - - 196.70% 56.31% -56.42% -80.39%
Earnings before Interest and Taxes (EBIT)		 -50 -76 -169 -205 -93 -121 -227 -177 -150 62 64
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -49 -75 -168 -205 -93 -119 -224 -174 -149 64 67
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -37 -43 -102 -114 59 -45 -182 -93 -64 20 21
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -1.03 -11 -28 -57 -182 -222 -198 -231 -276 -241 -220
Increase / (Decrease) in Invested Capital		 2.13 -10 -17 -29 -125 -40 24 -33 -45 34 21
Book Value per Share		 $12.76 $10.14 $9.34 $2.95 $0.73 ($3.45) ($6.77) ($4.39) ($4.00) ($1.97) ($1.26)
Tangible Book Value per Share		 $12.75 $10.13 $9.34 $2.95 $0.73 ($3.45) ($6.78) ($4.39) ($4.00) ($1.97) ($1.26)
Total Capital		 292 231 246 79 20 83 61 -64 -193 -96 -52
Total Debt		 4.29 2.73 1.05 0.00 0.00 179 258 260 262 292 249
Total Long-Term Debt		 2.69 1.02 0.00 0.00 0.00 179 258 260 262 238 249
Net Debt		 -288 -240 -273 -136 -202 -126 -1.05 93 179 148 82
Capital Expenditures (CapEx)		 0.30 0.09 0.02 0.15 0.95 0.87 0.00 0.00 0.00 0.32 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.89 -12 -28 -58 -56 -53 -3.71 -12 -37 1.58 -6.09
Debt-free Net Working Capital (DFNWC)		 210 200 172 78 146 252 256 154 45 146 162
Net Working Capital (NWC)		 209 198 171 78 146 252 256 154 45 92 162
Net Nonoperating Expense (NNE)		 15 22 49 59 32 59 110 108 100 106 65
Net Nonoperating Obligations (NNO)		 -288 -240 -273 -136 -202 -126 -1.05 93 179 148 82
Total Depreciation and Amortization (D&A)		 0.94 1.27 0.59 0.05 0.12 2.19 2.25 2.40 1.45 1.56 3.11
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($2.26) ($3.33) ($6.98) ($7.54) ($3.59) $0.00 ($9.31) ($3.52) ($2.03) ($0.28) ($0.11)
Adjusted Weighted Average Basic Shares Outstanding		 22.54M 22.56M 26.50M 26.82M 27.51M 0.00 28.90M 66.41M 103.11M 187.18M 207.87M
Adjusted Diluted Earnings per Share		 ($2.26) ($3.33) ($6.98) ($7.54) ($3.59) $0.00 ($9.31) ($3.52) ($2.03) ($0.28) ($0.11)
Adjusted Weighted Average Diluted Shares Outstanding		 22.54M 22.56M 26.50M 26.82M 27.51M 0.00 28.90M 66.41M 103.11M 187.18M 207.87M
Adjusted Basic & Diluted Earnings per Share		 ($2.26) ($3.33) ($6.98) ($7.54) ($3.59) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 22.02M 22.54M 23.93M 26.75M 27.09M 0.00 62.82M 76.57M 185.05M 197.85M 256.81M
Normalized Net Operating Profit after Tax (NOPAT)		 -35 -53 -118 -143 -65 -85 -159 -126 -109 38 42
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Quarterly Metrics And Ratios for Esperion Therapeutics

This table displays calculated financial ratios and metrics derived from Esperion Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 106,994,269.00 113,717,785.00 113,717,785.00 189,460,293.00 196,224,695.00 - 197,848,886.00 198,199,462.00 201,622,825.00 239,063,437.00 256,810,482.00
DEI Adjusted Shares Outstanding		 106,994,269.00 113,717,785.00 113,717,785.00 189,460,293.00 196,224,695.00 - 197,848,886.00 198,199,462.00 201,622,825.00 239,063,437.00 256,810,482.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.39 -0.50 0.54 -0.33 -0.15 - -0.20 -0.06 -0.16 0.26 -0.10
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 78.97% 71.38% 466.14% 186.33% 52.00% 114.30% -52.81% 11.58% 69.10% - 23.25%
EBITDA Growth		 33.86% 0.80% 254.13% 108.27% 48.42% 89.93% -129.39% 162.03% 34.96% - 72.09%
EBIT Growth		 33.85% 0.34% 252.69% 106.96% 47.55% 89.57% -130.57% 175.11% 31.04% - 70.22%
NOPAT Growth		 33.85% 0.34% 312.41% 106.96% 41.79% 85.10% -121.40% 175.11% 37.86% - 70.22%
Net Income Growth		 25.16% -1.54% 198.87% -24.01% 28.43% 62.16% -166.30% 79.45% -6.13% - 37.72%
EPS Growth		 54.32% 43.84% 143.04% 28.26% 59.46% 65.85% -161.76% 81.82% -6.67% - 52.38%
Operating Cash Flow Growth		 54.88% 12.75% 199.03% 70.89% -82.79% 5.68% -142.04% -336.11% 87.87% - -22.51%
Free Cash Flow Firm Growth		 2,054.59% 411.05% 987.82% 336.16% -211.94% -354.93% -126.63% -293.26% 17.81% - -45.13%
Invested Capital Growth		 -17.73% -19.46% -11.74% -8.55% 4.43% 12.50% 4.26% 18.33% 4.70% - 13.65%
Revenue Q/Q Growth		 31.73% -5.06% 327.09% -46.39% -30.07% 33.86% -5.96% 26.76% 5.98% - -52.45%
EBITDA Q/Q Growth		 26.13% -54.84% 273.40% -95.83% -560.87% 72.86% -406.30% 137.16% -214.40% - -106.94%
EBIT Q/Q Growth		 25.70% -53.88% 270.58% -96.43% -659.98% 72.42% -399.91% 132.11% -240.37% - -107.72%
NOPAT Q/Q Growth		 25.70% -53.88% 343.68% -97.50% -721.40% 60.60% -249.94% 132.11% -240.37% - -105.40%
Net Income Q/Q Growth		 17.39% -36.59% 208.30% -201.48% 52.32% 27.79% -89.77% 68.55% -146.23% - -140.75%
EPS Q/Q Growth		 19.57% -10.81% 182.93% -197.06% 54.55% 6.67% -50.00% 71.43% -166.67% - -131.25%
Operating Cash Flow Q/Q Growth		 21.92% -91.75% 245.26% -113.39% -390.28% 1.06% 35.26% -38.86% 86.36% - -161.27%
Free Cash Flow Firm Q/Q Growth		 285.29% -25.41% 552.22% -76.73% -198.88% -69.86% 31.86% -68.87% 57.94% - -159.71%
Invested Capital Q/Q Growth		 -5.59% -4.54% 6.08% -4.70% 7.03% 4.29% -2.76% 10.69% -8.50% - 2.87%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00%
EBITDA Margin		 -79.72% -130.02% 52.79% 4.11% -27.05% -6.11% -32.88% 9.64% -10.41% - -7.45%
Operating Margin		 -81.05% -131.37% 52.47% 3.49% -31.04% -6.40% -34.00% 8.61% -11.41% - -8.22%
EBIT Margin		 -81.05% -131.37% 52.47% 3.49% -27.97% -6.40% -34.00% 8.61% -11.41% - -8.22%
Profit (Net Income) Margin		 -121.43% -174.71% 44.30% -83.87% -57.18% -30.85% -62.24% -15.45% -35.89% - -31.45%
Tax Burden Percent		 96.99% 105.50% 104.77% 96.19% 100.00% -56.16% 97.42% 95.03% 97.89% - 95.52%
Interest Burden Percent		 154.46% 126.06% 80.59% -2,496.28% 204.43% -858.85% 187.94% -188.74% 321.42% - 400.84%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Equity (ROE)		 59.19% 53.74% 27.73% 27.51% 22.24% 12.27% 42.53% 26.75% 25.76% - 2.02%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Return on Assets (OROA)		 -31.23% -67.36% 38.58% 3.31% -30.87% -7.73% -25.32% 6.60% -10.22% - -8.74%
Return on Assets (ROA)		 -46.79% -89.59% 32.58% -79.39% -63.11% -37.30% -46.35% -11.84% -32.16% - -33.45%
Return on Common Equity (ROCE)		 59.19% 53.74% 27.73% 27.51% 22.24% 12.27% 42.53% 26.75% 25.76% - 2.02%
Return on Equity Simple (ROE_SIMPLE)		 50.83% 0.00% 29.39% 0.00% 0.00% 0.00% 35.95% 0.00% 0.00% - 0.00%
Net Operating Profit after Tax (NOPAT)		 -19 -30 72 1.81 -11 -4.42 -15 4.97 -6.97 85 -4.61
NOPAT Margin		 -56.74% -91.96% 52.47% 2.45% -21.73% -6.40% -23.80% 6.03% -7.98% - -5.75%
Net Nonoperating Expense Percent (NNEP)		 20.30% 19.60% 16.86% 65.22% 13.84% 10.34% 23.38% 12.40% 14.79% - 15.12%
Return On Investment Capital (ROIC_SIMPLE)		 - 15.33% -223.99% -2.21% 10.46% 4.58% 11.61% -3.67% 4.72% -162.39% 7.96%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
SG&A Expenses to Revenue		 137.23% 176.36% 37.80% 80.98% 110.90% 90.51% 114.68% 82.60% 95.22% - 97.00%
R&D to Revenue		 43.82% 55.01% 9.73% 15.52% 20.14% 15.88% 19.32% 8.79% 16.19% - 11.22%
Operating Expenses to Revenue		 181.05% 231.37% 47.53% 96.51% 131.04% 106.40% 134.00% 91.39% 111.41% - 108.22%
Earnings before Interest and Taxes (EBIT)		 -28 -42 72 2.58 -14 -4.42 -22 7.10 -9.96 85 -6.58
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -27 -42 73 3.03 -14 -4.22 -21 7.94 -9.09 86 -5.97
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Price to Revenue (P/Rev)		 1.02 2.92 1.33 1.51 1.10 1.30 1.10 0.73 1.76 - 1.68
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Revenue (EV/Rev)		 2.44 4.46 1.48 1.78 1.50 1.75 1.78 1.52 2.45 - 1.91
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 73.40 24.21 9.08 0.00 0.00 0.00 - 10.12
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 99.79 26.86 9.31 0.00 0.00 0.00 - 10.52
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 142.56 38.37 10.68 0.00 0.00 0.00 - 15.03
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 117.04 19.91 0.00 29.13 0.00 0.00 0.00 - 41.50
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 -0.64 -0.57 -0.89 -0.76 -0.71 -0.75 -0.69 -0.69 -0.67 - -0.81
Long-Term Debt to Equity		 -0.64 -0.57 -0.89 -0.76 -0.71 -0.61 -0.56 -0.56 -0.55 - -0.81
Financial Leverage		 -0.31 -0.35 -0.21 -0.27 -0.34 -0.39 -0.30 -0.37 -0.40 - -0.37
Leverage Ratio		 -0.76 -0.58 -1.00 -0.82 -0.69 -0.65 -0.97 -0.90 -0.83 - -1.07
Compound Leverage Factor		 -1.17 -0.73 -0.81 20.46 -1.40 5.59 -1.82 1.70 -2.65 - -4.29
Debt to Total Capital		 -175.47% -135.26% -812.13% -321.09% -245.06% -303.11% -219.93% -220.42% -205.56% - -432.17%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% -56.59% -41.04% -40.48% -37.14% - 0.00%
Long-Term Debt to Total Capital		 -175.47% -135.26% -812.13% -321.09% -245.06% -246.51% -178.89% -179.94% -168.42% - -432.17%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Common Equity to Total Capital		 275.47% 235.26% 912.13% 421.09% 345.06% 403.11% 319.93% 320.42% 305.56% - 532.17%
Debt to EBITDA		 -1.69 -1.76 -7.95 39.02 14.40 4.57 -7.69 -8.98 -11.36 - 3.17
Net Debt to EBITDA		 -0.95 -1.21 -1.07 10.88 6.48 2.31 -4.68 -6.39 -7.90 - 1.19
Long-Term Debt to EBITDA		 -1.69 -1.76 -7.95 39.02 14.40 3.72 -6.25 -7.33 -9.31 - 3.17
Debt to NOPAT		 -2.40 -2.40 -10.79 75.78 22.83 5.37 -10.47 -12.02 -14.76 - 4.71
Net Debt to NOPAT		 -1.34 -1.65 -1.46 21.13 10.26 2.71 -6.38 -8.55 -10.27 - 1.77
Long-Term Debt to NOPAT		 -2.40 -2.40 -10.79 75.78 22.83 4.37 -8.52 -9.81 -12.10 - 4.71
Altman Z-Score		 -8.85 -10.08 -3.41 -4.41 -5.43 -4.92 -6.11 -5.53 -5.34 - -3.17
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.58 1.29 2.22 1.97 1.85 1.37 1.18 1.15 1.00 - 1.53
Quick Ratio		 1.14 0.84 1.71 1.42 1.28 0.91 0.72 0.65 0.59 - 0.96
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 20 15 99 23 -23 -39 -26 -45 -19 64 -38
Operating Cash Flow to CapEx		 0.00% 0.00% 73,736.99% -9,357.14% -21,152.69% 0.00% 0.00% 0.00% 0.00% - -14,667.72%
Free Cash Flow to Firm to Interest Expense		 1.36 1.01 7.09 0.35 -1.52 0.00 -1.36 -2.18 -0.85 - -1.94
Operating Cash Flow to Interest Expense		 -1.29 -2.46 3.84 -0.11 -2.34 0.00 -1.16 -1.53 -0.19 - -1.40
Operating Cash Flow Less CapEx to Interest Expense		 -1.29 -2.46 3.83 -0.11 -2.35 0.00 -1.16 -1.53 -0.19 - -1.41
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.39 0.51 0.74 0.95 1.10 1.21 0.74 0.77 0.90 - 1.06
Accounts Receivable Turnover		 2.78 2.83 5.05 5.49 5.35 5.17 3.82 3.19 3.25 - 3.92
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.93
Fixed Asset Turnover		 785.51 0.00 1,309.06 1,638.87 2,058.89 0.00 1,046.67 1,055.61 1,332.46 - 1,551.93
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 1.84
Days Sales Outstanding (DSO)		 131.44 128.99 72.31 66.46 68.22 70.64 95.55 114.42 112.22 - 93.22
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 390.73
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 198.28
Cash Conversion Cycle (CCC)		 131.44 128.99 72.31 66.46 68.22 70.64 95.55 114.42 112.22 - 285.67
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -264 -276 -259 -271 -252 -241 -248 -221 -240 -220 -214
Invested Capital Turnover		 -0.42 -0.46 -0.94 -1.07 -1.15 -1.29 -1.02 -1.09 -1.23 - -1.81
Increase / (Decrease) in Invested Capital		 -40 -45 -27 -21 12 34 11 50 12 21 34
Enterprise Value (EV)		 251 519 340 494 442 581 463 407 745 - 798
Market Capitalization		 105 340 305 421 324 433 285 195 534 - 704
Book Value per Share		 ($3.83) ($4.00) ($1.74) ($1.82) ($1.89) ($1.97) ($2.15) ($2.19) ($2.24) ($1.26) ($1.20)
Tangible Book Value per Share		 ($3.83) ($4.00) ($1.74) ($1.82) ($1.89) ($1.97) ($2.15) ($2.19) ($2.24) ($1.26) ($1.20)
Total Capital		 -149 -193 -32 -82 -107 -96 -133 -135 -148 -52 -58
Total Debt		 261 262 262 262 263 292 293 298 304 249 250
Total Long-Term Debt		 261 262 262 262 263 238 238 243 249 249 250
Net Debt		 146 179 35 73 118 148 178 212 211 82 94
Capital Expenditures (CapEx)		 0.00 0.00 0.07 0.08 0.17 0.00 0.00 0.00 0.00 0.00 0.19
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -34 -37 -26 -20 -3.04 1.58 -12 13 -36 -6.09 2.94
Debt-free Net Working Capital (DFNWC)		 81 45 201 170 142 146 102 99 56 162 159
Net Working Capital (NWC)		 81 45 201 170 142 92 48 44 1.43 162 159
Net Nonoperating Expense (NNE)		 22 27 11 64 18 17 25 18 24 23 21
Net Nonoperating Obligations (NNO)		 146 179 35 73 118 148 178 212 211 82 94
Total Depreciation and Amortization (D&A)		 0.45 0.44 0.44 0.45 0.47 0.20 0.73 0.85 0.87 0.67 0.62
Debt-free, Cash-free Net Working Capital to Revenue		 -33.35% -32.15% -11.11% -7.03% -1.03% 0.48% -4.68% 4.66% -11.90% - 0.70%
Debt-free Net Working Capital to Revenue		 78.25% 38.55% 87.53% 61.12% 47.95% 44.04% 39.48% 36.76% 18.53% - 38.04%
Net Working Capital to Revenue		 78.25% 38.55% 87.53% 61.12% 47.95% 27.61% 18.42% 16.34% 0.47% - 38.04%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.37) ($0.41) $0.36 ($0.33) ($0.15) ($0.16) ($0.21) ($0.06) ($0.16) $0.32 ($0.10)
Adjusted Weighted Average Basic Shares Outstanding		 111.87M 103.11M 169.26M 188.79M 194.93M 187.18M 196.13M 197.55M 200.74M 207.87M 251.35M
Adjusted Diluted Earnings per Share		 ($0.37) ($0.41) $0.34 ($0.33) ($0.15) ($0.14) ($0.21) ($0.06) ($0.16) $0.32 ($0.10)
Adjusted Weighted Average Diluted Shares Outstanding		 111.87M 103.11M 189.64M 188.79M 194.93M 187.18M 196.13M 197.55M 200.74M 207.87M 251.35M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 113.72M 185.05M 189.46M 196.22M 197.04M 197.85M 198.20M 201.62M 239.06M 256.81M 257.43M
Normalized Net Operating Profit after Tax (NOPAT)		 -19 -30 51 1.81 -11 -3.09 -15 4.97 -6.97 60 -4.61
Normalized NOPAT Margin		 -56.74% -91.96% 36.73% 2.45% -21.73% -4.48% -23.80% 6.03% -7.98% - -5.75%
Pre Tax Income Margin		 -125.20% -165.60% 42.29% -87.19% -57.18% 54.93% -63.89% -16.25% -36.66% - -32.93%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -1.84 -2.81 5.15 0.04 -0.96 0.00 -1.14 0.35 -0.45 - -0.33
NOPAT to Interest Expense		 -1.29 -1.97 5.15 0.03 -0.74 0.00 -0.80 0.24 -0.32 - -0.23
EBIT Less CapEx to Interest Expense		 -1.84 -2.81 5.15 0.04 -0.97 0.00 -1.14 0.35 -0.45 - -0.34
NOPAT Less CapEx to Interest Expense		 -1.29 -1.97 5.15 0.03 -0.75 0.00 -0.80 0.24 -0.32 - -0.24
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% -664.32% -229.24% -337.67% -331.90% - 0.00%

Financials Breakdown Chart

Key Financial Trends

Here is a concise, data-driven snapshot of Esperion Therapeutics (ESPR) using the quarterly statements from the last four years. The focus is on profitability, cash flow, and balance-sheet health to help retail investors gauge ongoing risk and potential opportunities.

  • Q4 2025 net income attributable to common shareholders: $61,831,000 with basic/diluted earnings per share of $0.32, marking a profitable quarter after a stretch of losses.
  • Q4 2025 operating cash flow turned positive, with net cash from continuing operating activities of $45,243,000 and a net increase in cash of $75,405,000, improving near-term liquidity.
  • Q4 2025 gross margin around 23%, with gross profit of $39,222,000 on revenue of $168,446,000, signaling a viable gross platform before operating costs.
  • Q4 2025 financing activity included the issuance of common equity totaling $74,623,000, and net cash from continuing financing activities of $30,162,000, supporting liquidity from equity markets.
  • Current liquidity is tight but present, with Total Current Assets of $360.464M and Total Current Liabilities of $359.033M in Q3 2025 (roughly a 1.0x current ratio).
  • Negative shareholder equity persists across the period (Q3 2025 Total Equity of −$451.361M; Q2 2025 −$433.509M; Q1 2025 −$426.211M), signaling solvency risk even with positive quarters.
  • Leverage remains high; Total Liabilities of about $815.381M in Q3 2025 vs Total Assets of $364.020M, resulting in a large negative equity balance.
  • Profitability has been volatile; most quarters show net losses (for example Q1 2025 net income −$40.455M, Q2 2025 −$12.725M, Q3 2025 −$31.333M), with Q4 2025 as a rare profitable exception.
  • Interest expense remains a meaningful drag (Q4 2025: $22.636M; Q3 2025: $22.051M; Q2 2025: $20.486M; Q1 2025: $19.431M) relative to operating results.
  • Operating cash flow has been negative in several quarters (Q2 2025 CFO −$31.422M; Q3 2025 CFO −$4.286M; Q1 2025 CFO −$22.628M; Q4 2024 CFO −$34.952M), indicating ongoing cash burn despite occasional profitability on paper.
05/29/26 09:05 PM ETAI Generated. May Contain Errors.

Esperion Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Esperion Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

The last 5 years of Esperion Therapeutics' net income performance:
  • 2021: -$269.11 million
  • 2022: -$233.66 million
  • 2023: -$209.25 million
  • 2024: -$51.75 million
  • 2025: -$22.68 million
Find out what analysts predict for Esperion Therapeutics in the coming months.

Esperion Therapeutics' total operating income in 2025 was $60.27 million, based on the following breakdown:
  • Total Gross Profit: $273.91 million
  • Total Operating Expenses: $213.64 million

Over the last 10 years, Esperion Therapeutics' total revenue changed from $0.00 in 2015 to $403.14 million in 2025, a change of 40,313,500,000.0%.

Esperion Therapeutics' total liabilities were at $767.85 million at the end of 2025, a 4.8% increase from 2024, and a 9,136.7% increase since 2015.

In the past 10 years, Esperion Therapeutics' cash and equivalents has ranged from $34.47 million in 2017 to $304.96 million in 2020, and is currently $167.85 million as of their latest financial filing in 2025.

Over the last 10 years, Esperion Therapeutics' book value per share changed from 12.76 in 2015 to -1.26 in 2025, a change of -109.9%.


Related Companies

Financial statements for NASDAQ:ESPR last updated on 5/11/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel